This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buring, J. E. Articles by Dyken, M. Search for Related Content PubMed PubMed Citation Articles by Buring, J. E. Articles by Dyken, M.

(Stroke. 1998;29:885-886.)
© 1998 American Heart Association, Inc.

Editorial

Aspirin and Stroke

Julie E. Buring, ScD; Julien Bogousslavsky, MD; Mark Dyken, MD

From the Brigham and Women's Hospital, Boston, Mass (J.E.B.); Service de Neurologie, Centre Hospitalier Université Vaudois, Lausanne, Switzerland (J.B.); and the Stroke Editorial Office, Indiana University, Indianapolis, Ind (M.L.D.).

Correspondence to Julie E. Buring, ScD, Brigham and Women's Hospital, 900 Commonwealth Ave East, Boston, MA 02215. E-mail jeburing@bics.bwh.harvard.edu

Key Words: aspirin • stroke prevention

In this issue of Stroke, Kronmal and colleagues report the intriguing finding that in a cohort of elderly people, self-selection for aspirin use was associated with increased risks of ischemic stroke in women and hemorrhagic stroke in men and women. The authors are commendably cautious in their interpretation of the findings and raise the possibility of confounding by reasons for aspirin use as an explanation for the observed association. However, it is useful to view these findings in the context of the totality of available evidence.^{1 2}

Despite 100 years of widespread use, the potential for aspirin to affect risks of stroke has only been recognized relatively recently, due to the Nobel prize–winning work of Sir John Vane, who demonstrated that aspirin permanently inhibits cyclooxygenase-dependent platelet aggregation.³ Since that time, case-control and cohort studies conducted largely among middle-aged populations have suggested that individuals who self-select for aspirin therapy tend to have small (i.e., 20% to 30%) decreased risks of total and ischemic stroke.⁴ If true, such benefits would be clinically very worthwhile and would have an important public health impact. Unfortunately, however, the amount of uncontrolled and uncontrollable confounding in such studies, no matter how well designed and conducted, is likely to be as large as the effects being sought. In such circumstances, the most reliable design strategy to answer the question definitively is a large-scale randomized trial.⁵

In a collaborative worldwide overview of all randomized trials of antiplatelet agents, aspirin was shown to reduce the risk of nonfatal stroke by . . . [Full Text of this Article]

This article has been cited by other articles:

				K. S. Wong, V. Mok, W. W. M. Lam, R. Kay, A. Tang, Y. L. Chan, and J. Woo Aspirin-associated intracerebral hemorrhage: Clinical and radiologic features Neurology, June 27, 2000; 54(12): 2298 - 2301. [Abstract] [Full Text] [PDF]

				N. R. Cook, P. R. Hebert, J. E. Manson, J. E. Buring, and C. H. Hennekens Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians' Health Study Arch Intern Med, April 10, 2000; 160(7): 921 - 928. [Abstract] [Full Text] [PDF]